NORCROSS, Ga., Dec. 29 Immucor, Inc. (Nasdaq:BLUD), a global leader in providing automated instrument-reagent systems tothe blood transfusion industry, today announced that it expects to release itsfiscal second quarter earnings on Wednesday, January 7, 2009, after the closeof regular trading hours, and then host a conference call on Thursday, January8, 2009 at 8:30 AM (EST) to review the results. Investors are invited toparticipate in this conference call, with Dr. Gioacchino De Chirico, Presidentand Chief Executive Officer, Richard A. Flynt, Chief Financial Officer, andEdward L. Gallup, consultant. The call will focus on the results for thesecond quarter and general business trends. The earnings release will beposted on Immucor's website, as well as any material financial informationthat may be discussed by Dr. De Chirico, Mr. Flynt, or Mr. Gallup during thiscall that is not contained in the earnings release. Both the earnings releaseand the additional financial information, if any, will be posted as soon aspracticable after the call on the investor news section of Immucor's website.To access this information once posted, go to Immucor's website atwww.immucor.com and click on "About Us - Press Releases."
To participate in the telephone conference call, dial 1-888-324-7567 andpasscode BLUD. Replays of the conference call will be available for one weekbeginning at 12:00 noon on January 8th by calling 1-866-457-5510 and passcode2468. Beginning January 15, 2009, audio of the conference call or atranscript of the audio will be available on the "About Us - Press Releases"page of the Immucor website.
For more information on Immucor, please visit our website atwww.immucor.com.
Founded in 1982, Immucor manufactures and sells a complete line ofreagents and systems used by hospitals, reference laboratories and donorcenters to detect and identify certain properties of the cell and serumcomponents of blood prior to transfusion. Immucor markets a complete family ofautomated instrumentation for all of its market segments.
SOURCE Immucor, Inc.